Abstract
The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Current Diabetes Reviews
Title:Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Volume: 11 Issue: 1
Author(s): Friedrich Mittermayer, Erica Caveney, Claudia De Oliveira, Loukas Gourgiotis, Mala Puri, Li-Jung Tai and J. Rick Turner
Affiliation:
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Abstract: The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Export Options
About this article
Cite this article as:
Mittermayer Friedrich, Caveney Erica, De Oliveira Claudia, Gourgiotis Loukas, Puri Mala, Tai Li-Jung and Turner J. Rick, Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development, Current Diabetes Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573399810666141224121927
DOI https://dx.doi.org/10.2174/1573399810666141224121927 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-related Hypertension
Current Hypertension Reviews Artemia species: An Important Tool to Screen General Toxicity Samples
Current Pharmaceutical Design CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Current Topics in Medicinal Chemistry Buprenorphine-Mediated Transition from Opioid Agonist to Antagonist Treatment: State of the Art and New Perspectives
Current Drug Abuse Reviews Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Fused 1,4-Dihydropyridines as Potential Calcium Modulatory Compounds
Mini-Reviews in Medicinal Chemistry Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Diagnosis and Management of Hypertensive Emergencies Complicating Pregnancy
Current Women`s Health Reviews Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science Meet Our Associate Editor
Current Molecular Medicine Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Current Drug Targets